Pharmacentric Limited - Accounts to registrar (filleted) - small 18.2

Pharmacentric Limited - Accounts to registrar (filleted) - small 18.2


IRIS Accounts Production v21.1.6.35 05964690 director 1.11.19 31.10.20 31.10.20 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure059646902019-10-31059646902020-10-31059646902019-11-012020-10-31059646902018-10-31059646902018-11-012019-10-31059646902019-10-3105964690ns16:EnglandWales2019-11-012020-10-3105964690ns15:PoundSterling2019-11-012020-10-3105964690ns11:Director12019-11-012020-10-3105964690ns11:PrivateLimitedCompanyLtd2019-11-012020-10-3105964690ns11:SmallEntities2019-11-012020-10-3105964690ns11:AuditExempt-NoAccountantsReport2019-11-012020-10-3105964690ns11:SmallCompaniesRegimeForDirectorsReport2019-11-012020-10-3105964690ns11:SmallCompaniesRegimeForAccounts2019-11-012020-10-3105964690ns11:FullAccounts2019-11-012020-10-310596469012019-11-012020-10-3105964690ns11:RegisteredOffice2019-11-012020-10-3105964690ns6:CurrentFinancialInstruments2020-10-3105964690ns6:CurrentFinancialInstruments2019-10-3105964690ns6:Non-currentFinancialInstruments2020-10-3105964690ns6:Non-currentFinancialInstruments2019-10-3105964690ns6:ShareCapital2020-10-3105964690ns6:ShareCapital2019-10-3105964690ns6:RetainedEarningsAccumulatedLosses2020-10-3105964690ns6:RetainedEarningsAccumulatedLosses2019-10-3105964690ns6:NetGoodwill2019-11-012020-10-3105964690ns6:FurnitureFittings2019-11-012020-10-3105964690ns6:NetGoodwill2019-10-3105964690ns6:NetGoodwill2020-10-3105964690ns6:NetGoodwill2019-10-3105964690ns6:FurnitureFittings2019-10-3105964690ns6:FurnitureFittings2020-10-3105964690ns6:FurnitureFittings2019-10-3105964690ns6:CurrentFinancialInstrumentsns6:WithinOneYear2020-10-3105964690ns6:CurrentFinancialInstrumentsns6:WithinOneYear2019-10-3105964690ns6:BetweenTwoFiveYearsns6:Non-currentFinancialInstruments2020-10-3105964690ns6:BetweenTwoFiveYearsns6:Non-currentFinancialInstruments2019-10-31
REGISTERED NUMBER: 05964690 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 October 2020

for

Pharmacentric Limited

Pharmacentric Limited (Registered number: 05964690)

Contents of the Financial Statements
for the Year Ended 31 October 2020










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Pharmacentric Limited


Company Information
for the Year Ended 31 October 2020







DIRECTOR: Mr H Dodhia





REGISTERED OFFICE: 64 High Street
Elthorne Gate
Pinner
Middlesex
HA5 5QA





REGISTERED NUMBER: 05964690 (England and Wales)





ACCOUNTANTS: Aequitas
Chartered Accountants
Elthorne Gate
64 High Street
Pinner
HA5 5QA

Pharmacentric Limited (Registered number: 05964690)


Balance Sheet
31 October 2020

31.10.20 31.10.19
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 36,000 52,000
Property, plant and equipment 5 27,444 34,178
63,444 86,178

CURRENT ASSETS
Stock 91,726 79,894
Debtors 6 136,866 201,052
Cash at bank and in hand 341,269 56,261
569,861 337,207
CREDITORS
Amounts falling due within one year 7 407,461 353,704
NET CURRENT ASSETS/(LIABILITIES) 162,400 (16,497 )
TOTAL ASSETS LESS CURRENT LIABILITIES 225,844 69,681

CREDITORS
Amounts falling due after more than one
year

8

(50,000

)

-

PROVISIONS FOR LIABILITIES (5,214 ) -
NET ASSETS 170,630 69,681

Pharmacentric Limited (Registered number: 05964690)


Balance Sheet - continued
31 October 2020

31.10.20 31.10.19
Notes £    £    £    £   
CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 170,530 69,581
170,630 69,681

The Company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2020.

The members have not required the Company to obtain an audit of its financial statements for the year ended 31 October 2020 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the Company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the Company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the Company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 7 May 2021 and were signed by:





Mr H Dodhia - Director


Pharmacentric Limited (Registered number: 05964690)


Notes to the Financial Statements
for the Year Ended 31 October 2020


1. STATUTORY INFORMATION

Pharmacentric Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The presentation currency of the financial statements is the Pound Sterling (£) which is also the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

Turnover
Turnover represents revenue generated from the dispensing chemist and is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discount, settlement discounts and volume rebates.

Goodwill
Positive goodwill is capitalised, classified as an asset on the balance sheet and amortised on a straight line basis over its useful economic life. It is reviewed for impairment at the end of the first full financial year following the acquisition and in other periods if events or changes in circumstances indicate that the carrying value may not be recoverable.

Goodwill, being the amount paid in connection with the acquisition of a business in 2008, is being amortised evenly at 15 years in straight line basis.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 20% on reducing balance

Government grants
Grants relating to revenue are recognised in income on a systematic basis over the periods in which the entity recognises the related costs for which the grant is intended to compensate. A grant that becomes receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised as other operating income in the Statement of Income and Retained Earnings in the period in which it becomes receivable.

Stocks
Stock are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Pharmacentric Limited (Registered number: 05964690)


Notes to the Financial Statements - continued
for the Year Ended 31 October 2020


2. ACCOUNTING POLICIES - continued

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 7 (2019 - 8 ) .

Pharmacentric Limited (Registered number: 05964690)


Notes to the Financial Statements - continued
for the Year Ended 31 October 2020


4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 November 2019
and 31 October 2020 240,000
AMORTISATION
At 1 November 2019 188,000
Amortisation for year 16,000
At 31 October 2020 204,000
NET BOOK VALUE
At 31 October 2020 36,000
At 31 October 2019 52,000

5. PROPERTY, PLANT AND EQUIPMENT
Fixtures
and
fittings
£   
COST
At 1 November 2019
and 31 October 2020 123,811
DEPRECIATION
At 1 November 2019 89,633
Charge for year 6,734
At 31 October 2020 96,367
NET BOOK VALUE
At 31 October 2020 27,444
At 31 October 2019 34,178

Pharmacentric Limited (Registered number: 05964690)


Notes to the Financial Statements - continued
for the Year Ended 31 October 2020


6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.10.20 31.10.19
£    £   
Trade debtors 103,003 176,305
VAT 29,629 13,305
Deferred tax asset - 6,842
Prepayments and accrued income 4,234 4,600
136,866 201,052

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.10.20 31.10.19
£    £   
Trade creditors 133,024 158,582
Taxation and social security 23,949 (630 )
Other creditors 250,488 195,752
407,461 353,704

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
31.10.20 31.10.19
£    £   
Bank loans (see note 9) 50,000 -

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more than 5 years 10,000 -

9. LOANS

An analysis of the maturity of loans is given below:

31.10.20 31.10.19
£    £   
Amounts falling due between two and five years:
Bank loans - 2-5 years 40,000 -

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more than 5 years 10,000 -

Pharmacentric Limited (Registered number: 05964690)


Notes to the Financial Statements - continued
for the Year Ended 31 October 2020


10. OTHER FINANCIAL COMMITMENTS

As at the balance sheet date the total financial commitments are £109,841. This commitments are in for operating lease commitment for rent of the premises.